Loading...
XSHE002644
Market cap522mUSD
Jan 10, Last price  
7.50CNY
1D
-2.60%
1Q
2.60%
Jan 2017
-33.63%
IPO
130.77%
Name

Lanzhou Foci Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002644 chart
P/E
57.00
P/S
3.29
EPS
0.13
Div Yield, %
0.73%
Shrs. gr., 5y
—
Rev. gr., 5y
16.39%
Revenues
1.16b
+14.12%
177,489,856219,012,177232,209,322262,406,038271,184,334266,362,196291,528,279399,071,335327,584,499363,255,420501,139,716544,581,046628,815,164668,051,013817,640,8261,019,176,3391,163,134,313
Net income
67m
-38.16%
23,312,60721,609,21436,146,83351,241,69232,060,66230,356,20430,596,42734,652,86442,947,62160,926,23874,092,78272,918,22971,107,018108,017,96693,258,956108,654,17467,189,706
CFO
66m
-9.20%
105,608,341602,5633,464,82956,179,2632,426,0310093,746,66464,114,41656,901,04466,423,06236,663,11247,822,98562,888,16211,854,64272,369,95665,714,299
Dividend
Jun 25, 20240.03 CNY/sh
Earnings
Apr 30, 2025

Profile

LanZhou Foci Pharmaceutical Co.,Ltd., a pharmaceutical company, manufactures and sells traditional Chinese medicines in China. It offers its products in various dosage forms, including pills, tablets, capsules, and granules under the Min Shan and Foci brands. The company also engages in researching activities for the development of new herbal drugs. It also exports its products to approximately 27 countries, which include the United States, Canada, Japan, Australia, Russia, Ukraine, Singapore, Indonesia, Thailand, Malaysia, New Zealand, Hong Kong, etc. The company was founded in 1929 and is based in Lanzhou, China. LanZhou Foci Pharmaceutical Co.,Ltd. is a subsidiary of Lanzhou Foci Pharmaceutical Factory.
URL
http://www.fczy.com
IPO date
Dec 22, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,163,134
14.12%
1,019,176
24.65%
Cost of revenue
1,007,576
872,085
Unusual Expense (Income)
NOPBT
155,559
147,092
NOPBT Margin
13.37%
14.43%
Operating Taxes
13,520
21,069
Tax Rate
8.69%
14.32%
NOPAT
142,039
126,023
Net income
67,190
-38.16%
108,654
16.51%
Dividends
(27,944)
(5,107)
Dividend yield
0.56%
0.11%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
10,000
13,839
Long-term debt
2,692
1,062
Deferred revenue
260,964
278,150
Other long-term liabilities
26,600
40,366
Net debt
(457,452)
(450,220)
Cash flow
Cash from operating activities
65,714
72,370
CAPEX
(22,473)
Cash from investing activities
(34,155)
(42,850)
Cash from financing activities
(25,001)
FCF
112,703
74,419
Balance
Cash
406,041
398,455
Long term investments
64,103
66,666
Excess cash
411,987
414,162
Stockholders' equity
1,311,123
1,428,222
Invested Capital
1,655,353
1,583,272
ROIC
8.77%
8.10%
ROCE
7.51%
7.35%
EV
Common stock shares outstanding
510,657
510,657
Price
9.75
4.50%
9.33
-7.07%
Market cap
4,978,906
4.50%
4,764,430
-7.07%
EV
4,544,513
4,332,794
EBITDA
208,045
196,635
EV/EBITDA
21.84
22.03
Interest
1,473
678
Interest/NOPBT
0.95%
0.46%